EdgeMarket › What Defilade Capital Management, L.P. reported owning
What Defilade Capital Management, L.P. reported owning
As filed on Form 13F for the quarter ending 2026-03-31, up to 45 days after that date. Long-only US-listed equity — shorts, bonds, cash and non-US listings are not on the form, so this is one leg of the book, not the book.
Reported value
712.2MPositions
31Quarter
2026-03-31Shown below
31largest by value
| holding | value | % of book | shares | price | 1y |
|---|---|---|---|---|---|
| ZBH ZIMMER BIOMET HOLDINGS, INC. | 52.4M | 7.4% | 579.2K | 100.98 | -4.5% |
| HSIC HENRY SCHEIN INC | 46.0M | 6.5% | 624.0K | 88.50 | +28.9% |
| BDX BECTON DICKINSON & CO | 43.9M | 6.2% | 279.2K | 192.00 | -3.6% |
| PTCT PTC THERAPEUTICS, INC. | 41.1M | 5.8% | 376.2K | 69.82 | +42.9% |
| DXCM DEXCOM INC | 33.8M | 4.8% | 538.8K | 92.34 | +13.1% |
| ICUI ICU MEDICAL INC/DE | 32.8M | 4.6% | 254.3K | 182.84 | +48.2% |
| INSM INSMED Inc | 31.9M | 4.5% | 194.9K | 125.77 | -2.8% |
| ISRG INTUITIVE SURGICAL INC | 31.2M | 4.4% | 67.7K | 378.81 | -21.2% |
| RVMD Revolution Medicines, Inc. | 30.7M | 4.3% | 316.0K | 209.46 | +479.3% |
| GMED GLOBUS MEDICAL INC | 30.5M | 4.3% | 354.4K | 86.91 | +43.1% |
| NBIX NEUROCRINE BIOSCIENCES INC | 27.7M | 3.9% | 209.9K | 152.57 | +14.5% |
| DNLI Denali Therapeutics Inc. | 26.1M | 3.7% | 1.4M | 24.92 | +71.7% |
| PACS PACS Group, Inc. | 25.6M | 3.6% | 604.2K | 44.25 | +271.2% |
| OLMA Olema Pharmaceuticals, Inc. | 22.4M | 3.1% | 1.5M | 10.69 | +96.1% |
| ELAN Elanco Animal Health Inc | 22.3M | 3.1% | 931.1K | 23.97 | +37.3% |
| PFE PFIZER INC | 19.4M | 2.7% | 1.5M | 28.07 | +10.6% |
| LLY ELI LILLY & Co | 19.0M | 2.7% | 20.7K | 1,255.40 | +78.0% |
| LNTH Lantheus Holdings, Inc. | 18.9M | 2.7% | 249.4K | 99.97 | +78.1% |
| ITGR Integer Holdings Corp | 18.7M | 2.6% | 213.0K | 125.20 | +16.7% |
| BIIB BIOGEN INC. | 17.7M | 2.5% | 96.3K | 216.78 | +56.0% |
| EVMN Evommune, Inc. | 15.6M | 2.2% | 678.6K | 14.02 | — |
| TNDM TANDEM DIABETES CARE INC | 14.6M | 2.1% | 761.9K | 22.32 | +109.0% |
| COGT Cogent Biosciences, Inc. | 13.6M | 1.9% | 352.6K | 36.73 | +209.6% |
| unmapped CUSIP 670703107 | 13.3M | 1.9% | 129.9K | — | — |
| OCUL OCULAR THERAPEUTIX, INC | 12.6M | 1.8% | 1.5M | 11.08 | -7.4% |
| ASND Ascendis Pharma A/S | 11.9M | 1.7% | 51.9K | 253.29 | +31.4% |
| ALGN ALIGN TECHNOLOGY INC | 11.5M | 1.6% | 67.3K | 162.55 | +13.2% |
| ELDN Eledon Pharmaceuticals, Inc. | 11.0M | 1.5% | 3.6M | 3.45 | +33.7% |
| ORIC Oric Pharmaceuticals, Inc. | 10.7M | 1.5% | 842.9K | 14.20 | +49.3% |
| BHVN Biohaven Ltd. | 2.7M | 0.4% | 315.9K | 13.85 | -5.8% |
| MREO Mereo BioPharma Group plc | 2.5M | 0.4% | 7.6M | 0.29 | -82.2% |
A position that grew quarter on quarter may simply reflect a higher price: if the stock rose 40% and the manager did nothing, the reported value rose 40%. Reading that as accumulation is reading the price back to yourself. More on that →
The whole archive is one click away.
Screener, filings, insider flow, backtests and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →